The Pfizer vaccine will deal with new mutations in the SARS-CoV-2 coronavirus Most of the SARS-CoV-2 coronavirus mutations we have seen so far have had little effect on its characteristics, and what's more, we had a vaccine on the way.

Everything changed a while ago when we heard about the British strain of the coronavirus, which is likely to be more contagious. And since it appeared after the vaccination process had started, questions arose as to whether the vaccine was prepared for it. Scientists, of course, immediately began to carry out the relevant research, and as the conclusions have just published, there is no reason to worry, because the vaccine from Pfizer and BioNTech is effective in the fight against 16 different mutations of the coronavirus, including the "British". According to Reuters, the vaccine does not need to be modified Web News order to counteract a virus that appears to be more contagious than others, according to a study by researchers at Pfizer and the University of Texas.

This one was called B117 and although it appeared in Great Britain, it is now also found elsewhere in the world, such as the United States, among people who have not traveled to the UK, so its prevalence is only a matter of time. It is worth remembering, however, that there is currently no evidence that it is more dangerous than previous strains, and we have confirmation that the vaccine is just as effective against it: - We tested 16 different mutations and none of them have a significant impact on the virus. This is good news. Of course, this does not mean that 5pm will not have either, explains one of Pfizer's scientists, Phil Dormitzer.

Is this last indication just a theorizing, or is it pointing to another mutation that has gotten loud recently, namely the one in South Africa? It's hard to say, especially since local scientists have suggested that this may be more problematic, but we'll only see everything in a few weeks: 'It's just a theoretical concern, but it is justified that the South African variant may be more resilient,' Professor Shabir Madhi said at the time in a speech for BBC. At the same time, however, he pointed out that theoretically we are dealing with a different virus than the one in Great Britain, but at the same time, both have the same N501Y mutation, which is most likely responsible for the increased transmission rate, so the vaccine may be able to handle this strain without any modifications. Time will tell.